Neogenomics Stock Price Prediction

NEO Stock  USD 16.39  1.00  6.50%   
The relative strength index (RSI) of NeoGenomics' share price is above 70 as of today. This indicates that the stock is becoming overbought or overvalued. The idea behind Relative Strength Index (RSI) is that it helps to track how fast people are buying or selling NeoGenomics, making its price go up or down.

Oversold Vs Overbought

70

 
Oversold
 
Overbought
The successful prediction of NeoGenomics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with NeoGenomics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting NeoGenomics' stock price prediction:
Quarterly Earnings Growth
1.306
EPS Estimate Next Quarter
0.04
EPS Estimate Current Year
0.0983
EPS Estimate Next Year
0.2008
Wall Street Target Price
20.9091
Using NeoGenomics hype-based prediction, you can estimate the value of NeoGenomics from the perspective of NeoGenomics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in NeoGenomics to buy its stock at a price that has no basis in reality. In that case, they are not buying NeoGenomics because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

NeoGenomics after-hype prediction price

    
  USD 15.39  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out NeoGenomics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NeoGenomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
12.5915.0717.56
Details
Naive
Forecast
LowNextHigh
11.6514.1516.64
Details
13 Analysts
Consensus
LowTargetHigh
18.5320.3622.60
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.020.020.04
Details

NeoGenomics After-Hype Price Prediction Density Analysis

As far as predicting the price of NeoGenomics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in NeoGenomics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of NeoGenomics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

NeoGenomics Estimiated After-Hype Price Volatility

In the context of predicting NeoGenomics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on NeoGenomics' historical news coverage. NeoGenomics' after-hype downside and upside margins for the prediction period are 12.90 and 17.88, respectively. We have considered NeoGenomics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
16.39
15.39
After-hype Price
17.88
Upside
NeoGenomics is not too volatile at this time. Analysis and calculation of next after-hype price of NeoGenomics is based on 3 months time horizon.

NeoGenomics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as NeoGenomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeoGenomics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NeoGenomics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.07 
2.49
  0.10 
  0.20 
8 Events / Month
12 Events / Month
In about 8 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
16.39
15.39
0.00 
180.43  
Notes

NeoGenomics Hype Timeline

On the 22nd of November NeoGenomics is traded for 16.39. The entity has historical hype elasticity of 0.1, and average elasticity to hype of competition of -0.2. NeoGenomics is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is about 180.43%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.07%. %. The volatility of related hype on NeoGenomics is about 85.12%, with the expected price after the next announcement by competition of 16.19. About 100.0% of the company shares are owned by institutional investors. The book value of NeoGenomics was now reported as 7.09. The company has Price/Earnings (P/E) ratio of 272.37. NeoGenomics recorded a loss per share of 0.61. The entity had not issued any dividends in recent years. The firm had 1:100 split on the 16th of April 2003. Considering the 90-day investment horizon the next forecasted press release will be in about 8 days.
Check out NeoGenomics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

NeoGenomics Related Hype Analysis

Having access to credible news sources related to NeoGenomics' direct competition is more important than ever and may enhance your ability to predict NeoGenomics' future price movements. Getting to know how NeoGenomics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how NeoGenomics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
NTRANatera Inc 5.41 8 per month 2.27  0.13  4.30 (3.75) 25.26 
QGENQiagen NV 0.85 10 per month 0.00 (0.20) 2.06 (2.05) 5.80 
NEOGNeogen 0.75 13 per month 0.00 (0.09) 4.11 (6.46) 11.75 
GHGuardant Health 0.03 9 per month 2.90  0.03  7.53 (5.16) 17.48 
CDNACaredx Inc 1.59 11 per month 0.00 (0.17) 4.05 (6.49) 24.22 
MYGNMyriad Genetics(0.02)10 per month 0.00 (0.28) 4.24 (6.12) 27.15 
CSTLCastle Biosciences(0.41)11 per month 2.79 (0.0001) 5.90 (4.38) 19.49 
SYNHSyneos Health 0.00 0 per month 0.85  0  2.13 (1.42) 9.20 
MTDMettler Toledo International(60.36)6 per month 0.00 (0.19) 2.61 (3.37) 12.16 
ICLRICON PLC 9.24 10 per month 0.00 (0.20) 4.13 (4.22) 24.50 
IQVIQVIA Holdings(0.76)11 per month 0.00 (0.24) 1.66 (4.05) 9.22 
CRLCharles River Laboratories(5.46)10 per month 0.00 (0.06) 2.78 (4.35) 18.19 
SHCSotera Health Co 0.1 8 per month 0.00 (0.17) 3.45 (3.99) 11.98 
OLKOlink Holding AB 0.01 10 per month 0.48  0.08  1.58 (1.37) 4.37 
ACRSAclaris Therapeutics 0.02 9 per month 2.92  0.21  15.47 (5.51) 66.90 
TWSTTwist Bioscience Corp(0.69)10 per month 0.00 (0.03) 6.77 (6.21) 17.59 
BDSXBiodesix(0.03)8 per month 0.00 (0.15) 4.97 (5.61) 29.48 

NeoGenomics Additional Predictive Modules

Most predictive techniques to examine NeoGenomics price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for NeoGenomics using various technical indicators. When you analyze NeoGenomics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About NeoGenomics Predictive Indicators

The successful prediction of NeoGenomics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as NeoGenomics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of NeoGenomics based on analysis of NeoGenomics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to NeoGenomics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NeoGenomics's related companies.
 2022 2023 2024 (projected)
Days Sales Outstanding85.7280.9670.22
PTB Ratio1.152.162.05

Story Coverage note for NeoGenomics

The number of cover stories for NeoGenomics depends on current market conditions and NeoGenomics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that NeoGenomics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about NeoGenomics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

NeoGenomics Short Properties

NeoGenomics' future price predictability will typically decrease when NeoGenomics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of NeoGenomics often depends not only on the future outlook of the potential NeoGenomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeoGenomics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding125.5 M
Cash And Short Term Investments415.2 M
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.61)
Revenue Per Share
5.098
Quarterly Revenue Growth
0.104
Return On Assets
(0.03)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.